Cormark Equities Analysts Decrease Earnings Estimates for Cardiome Pharma Corp (COM)

Cardiome Pharma Corp (TSE:COM) (NASDAQ:CRME) – Equities research analysts at Cormark dropped their FY2017 earnings estimates for shares of Cardiome Pharma Corp in a report issued on Wednesday. Cormark analyst D. Novak now forecasts that the biopharmaceutical company will post earnings of ($0.93) per share for the year, down from their previous estimate of ($0.84).

COPYRIGHT VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.com-unik.info/2017/08/12/cormark-equities-analysts-decrease-earnings-estimates-for-cardiome-pharma-corp-com.html.

Separately, HC Wainwright restated a “buy” rating on shares of Cardiome Pharma Corp in a research note on Wednesday, May 17th.

Shares of Cardiome Pharma Corp (TSE COM) opened at 5.05 on Friday. The company’s market cap is $163.83 million. Cardiome Pharma Corp has a 12-month low of $3.25 and a 12-month high of $6.06. The firm’s 50-day moving average price is $5.58 and its 200 day moving average price is $4.72.

In related news, insider Justin Renz purchased 10,000 shares of the business’s stock in a transaction on Wednesday, May 17th. The shares were bought at an average cost of C$3.52 per share, with a total value of C$35,200.00.

About Cardiome Pharma Corp

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.

What are top analysts saying about Cardiome Pharma Corp? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cardiome Pharma Corp and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit